Dr. Eric L. Simpson, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 403
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
OR license MD23920
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 403
- Services billed
- 1,562
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 445 | 94 |
| Established patient office or other outpatient visit, 20-29 minutes | 297 | 249 |
| Destruction of precancer skin growth, 1 growth | 157 | 123 |
| Established patient office or other outpatient visit, 30-39 minutes | 95 | 81 |
| Biopsy of related skin growth, first growth | 79 | 72 |
| Biopsy of related skin growth, each additional growth | 27 | 18 |
| Established patient office or other outpatient visit, 10-19 minutes | 23 | 22 |
| Destruction of skin growth, 1-14 growths | 21 | 16 |
| New patient office or other outpatient visit, 30-44 minutes | 19 | 19 |
| Punch biopsy, first skin growth | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dupixent Pen (dupilumab) Other prescribers in Portland, OR | 63 |
| Triamcinolone Acetonide Other prescribers in Portland, OR | 49 |
| Clobetasol Propionate Other prescribers in Portland, OR | 42 |
| Tacrolimus Other prescribers in Portland, OR | 37 |
| Dupixent Syringe (dupilumab) Other prescribers in Portland, OR | 34 |
| Methotrexate (methotrexate sodium) Other prescribers in Portland, OR | 20 |
| Hydrocortisone Other prescribers in Portland, OR | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 98 payments worth $200,052 in total to this clinician.
| Genzyme Corporation | $121,152 |
|---|---|
| Pfizer Inc. | $33,407 |
| Amgen Inc. | $10,521 |
| Regeneron Pharmaceuticals, Inc. | $9,406 |
| Galderma Laboratories, L.P. | $7,274 |
| Roche Products Limited | $4,428 |
| Leo Pharma As | $3,608 |
| Leo Pharma Inc. | $2,733 |
| Compensation for services other than consulting (speaking, faculty) | $121,285 |
|---|---|
| Consulting Fee | $61,567 |
| Travel and Lodging | $13,698 |
| Honoraria | $2,440 |
| Food and Beverage | $1,062 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation May 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $43,407 |
| Genzyme Corporation Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $38,391 |
| Pfizer Inc. Jul 7, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $17,520 |
| Genzyme Corporation Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $9,775 |
| Genzyme Corporation Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $9,741 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisbon, Portugal · in-kind | $5,830 |
| Genzyme Corporation Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $4,888 |
| Roche Products Limited Feb 22, 2025 | Consulting Fee | $4,428 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,392 |
| Genzyme Corporation Apr 5, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,725 |
All 74 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $3,000 |
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $1,500 |
| Galderma Laboratories, L.P. Dec 8, 2025 | Consulting Fee NEMLUVIO · DERMATITIS Company’s descriptionGalderma Global Medical EADV Ad Board Meeting | $3,400 |
| Galderma Laboratories, L.P. Dec 8, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to PARIS, France · in-kind Company’s descriptionGalderma Global Medical EADV Ad Board Meeting | $3,374 |
| Galderma Laboratories, L.P. Dec 8, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to PARIS, France · in-kind Company’s descriptionGalderma Global Medical EADV Ad Board Meeting | $499 |
| Amgen Inc. Nov 25, 2025 | Consulting Fee | $2,620 |
| Genzyme Corporation Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,250 |
| Amgen Inc. Nov 12, 2025 | Consulting Fee | $2,835 |
| Leo Pharma As Nov 12, 2025 | Consulting Fee | $1,143 |
| Amgen Inc. Nov 12, 2025 | Travel and Lodging travel to Paris, France | $620 |
| Leo Pharma As Nov 12, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $250 |
| Amgen Inc. Nov 12, 2025 | Travel and Lodging travel to Paris, France | $4.69 |
| Leo Pharma As Nov 12, 2025 | Consulting Fee | $1.82 |
| Pfizer Inc. Oct 23, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $1,500 |
| Pfizer Inc. Oct 10, 2025 | Honoraria | $1,433 |
| Pfizer Inc. Oct 10, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $11.32 |
| Amgen Inc. Sep 23, 2025 | Consulting Fee | $1,965 |
| Amgen Inc. Sep 21, 2025 | Travel and Lodging travel to Paris, France · in-kind | $35.63 |
| Leo Pharma As Sep 21, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $13.97 |
| Amgen Inc. Sep 20, 2025 | Travel and Lodging travel to Paris, France · in-kind | $68.54 |
| Leo Pharma As Sep 20, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $26.87 |
| Amgen Inc. Sep 19, 2025 | Travel and Lodging travel to Paris, France · in-kind | $68.54 |
| Leo Pharma As Sep 19, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $26.87 |
| Amgen Inc. Sep 18, 2025 | Travel and Lodging travel to Paris, France · in-kind | $68.54 |
| Leo Pharma As Sep 18, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $26.87 |
| Amgen Inc. Sep 17, 2025 | Travel and Lodging travel to Paris, France · in-kind | $68.54 |
| Leo Pharma As Sep 17, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $26.87 |
| Amgen Inc. Sep 16, 2025 | Travel and Lodging travel to Paris, France · in-kind | $68.54 |
| Leo Pharma As Sep 16, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $26.87 |
| Amgen Inc. Sep 15, 2025 | Travel and Lodging travel to Paris, France · in-kind | $28.80 |
| Leo Pharma As Sep 15, 2025 | Travel and Lodging travel to PARIS, France · in-kind | $11.29 |
| Leo Pharma Inc. Sep 8, 2025 | Consulting Fee | $2,715 |
| Pfizer Inc. Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) CIBINQO · Inflammation & Immunology · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) CIBINQO · Inflammation & Immunology · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. Jul 7, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $17,520 |
| Genzyme Corporation Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $9,775 |
| Genzyme Corporation Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,208 |
| Genzyme Corporation Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $4,888 |
| Genzyme Corporation May 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $43,407 |
| Janssen Biotech, Inc. May 5, 2025 | Consulting Fee TREMFYA · Immunology | $1,996 |
| Janssen Biotech, Inc. May 5, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL | $3.60 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,392 |
| Leo Pharma As Apr 16, 2025 | Consulting Fee | $1,996 |
| Amgen Inc. Apr 16, 2025 | Consulting Fee ENBREL · Inflammation | $1,996 |
| Incyte Corporation Apr 16, 2025 | Consulting Fee | $1,160 |
| Leo Pharma As Apr 16, 2025 | Travel and Lodging travel to ORLANDO, FL | $3.60 |
| Amgen Inc. Apr 16, 2025 | Travel and Lodging ENBREL · Inflammation · travel to ORLANDO, FL | $3.60 |
| Incyte Corporation Apr 16, 2025 | Travel and Lodging travel to Orlando, FL | $2.09 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisbon, Portugal · in-kind | $5,830 |
| Genzyme Corporation Apr 5, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,725 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisbon, Portugal · in-kind | $752 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisbon, Portugal · in-kind | $411 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisboa, Portugal | $128 |
| Pfizer Inc. Apr 4, 2025 | Honoraria | $1,007 |
| Pfizer Inc. Apr 4, 2025 | Travel and Lodging travel to ORLANDO, FL · in-kind | $13.42 |
| Genzyme Corporation Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $38,391 |
| Leo Pharma As Mar 9, 2025 | Travel and Lodging travel to ORLANDO, FL | $10.49 |
| Amgen Inc. Mar 9, 2025 | Travel and Lodging ENBREL · Inflammation · travel to ORLANDO, FL · in-kind | $10.49 |
| Incyte Corporation Mar 9, 2025 | Travel and Lodging travel to Orlando, FL | $6.10 |
| Genzyme Corporation Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $9,741 |
| Genzyme Corporation Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,343 |
| Regeneron Healthcare Solutions, Inc. Mar 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,388 |
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,194 |
| Regeneron Pharmaceuticals, Inc. Mar 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $478 |
| Leo Pharma As Mar 6, 2025 | Travel and Lodging travel to ORLANDO, FL | $12.50 |
| Amgen Inc. Mar 6, 2025 | Travel and Lodging ENBREL · Inflammation · travel to ORLANDO, FL · in-kind | $12.50 |
| Incyte Corporation Mar 6, 2025 | Travel and Lodging travel to Orlando, FL | $7.26 |
| Janssen Biotech, Inc. Mar 3, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $12.50 |
| Janssen Biotech, Inc. Mar 3, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $10.49 |
| Roche Products Limited Feb 22, 2025 | Consulting Fee | $4,428 |
| Hoffmann-la Roche Limited Feb 21, 2025 | Travel and Lodging travel to San Francisco, CA | $549 |
| Hoffmann-la Roche Limited Feb 21, 2025 | Travel and Lodging travel to San Francisco, CA | $395 |
| Hoffmann-la Roche Limited Feb 21, 2025 | Travel and Lodging travel to San Francisco, CA | $199 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 5 companies. The companies reported $341,053 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sanofi US Services Inc. · Active, not recruiting · NCT06241118 - Effects of interleukin (il)-4/IL-13 blockade on the structure and function of cutaneous sensory nerves
Regeneron Pharmaceuticals, Inc. - Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Regeneron Pharmaceuticals, Inc. · Completed · NCT02612454 - Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Regeneron Pharmaceuticals, Inc. · Completed · NCT05590585 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc. - M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc. - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Active, not recruiting · NCT03568318 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie Inc. · Active, not recruiting · NCT06389136 - An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS)
Incyte Corporation - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
AbbVie Inc. · Completed · NCT03569293
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.